CRISPR Therapeutics is led by Dr. Samarth Kulkarni, who serves as the Chief Executive Officer. He has guided the gene-editing pioneer through critical clinical milestones, regulatory approvals for its landmark CRISPR/Cas9-based therapies, and strategic commercial partnerships designed to expand genetic medicine applications globally.